@article{4f3948f80b7b4a1aa3c6290aacea6245,
title = "Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC",
author = "Samuel Rosner and Forde, \{Patrick M.\}",
note = "Funding Information: Disclosure: Dr. Forde reports receiving payments to his institution from AstraZeneca, Bristol-Myers Squibb, Novartis, Corvus, Array, and Kyowa; receiving consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, G1, Surface, F Star, Iteos, Janssen, Novartis, Daichii Sankyo, and Sanofi; having advisory board participation with Polaris and Flame; and having participation with LUNGevity, MARF, and Cancer Trials Ireland. Dr. Rosner declares no conflict of interest.",
year = "2022",
month = apr,
doi = "10.1016/j.jtho.2022.02.007",
language = "English (US)",
volume = "17",
pages = "503--509",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "4",
}